Metformin is a biguanide oral anti-diabetic medication and arguably the most well-studied drug in the world for metabolic health, insulin sensitivity, and longevity. For bodybuilders and PED users, Metformin serves multiple purposes: improving insulin sensitivity (which AAS and growth hormone can impair), enhancing nutrient partitioning toward muscle rather than fat, managing blood glucose on GH/insulin protocols, and providing potential longevity benefits through AMPK activation. It is the go-to pharmaceutical for managing the metabolic side effects of AAS use, particularly during bulking phases where excess caloric intake combined with hormonal changes can promote insulin resistance.
Notes
Metformin was discovered in the 1920s, derived from the French lilac (Galega officinalis) which was used in medieval herbal medicine. It was approved in Europe in 1957 and in the US in 1995. The TAME (Targeting Aging with Metformin) trial is a landmark study investigating metformin's anti-aging effects in non-diabetic adults. For PED users, metformin is most valuable during GH-inclusive protocols and bulking phases where insulin sensitivity is compromised. The mTOR suppression is a double-edged sword — beneficial for longevity and cancer prevention, but potentially counterproductive for maximum muscle hypertrophy.
Metformin's primary mechanism is AMPK (AMP-activated protein kinase) activation, though it acts through multiple pathways: (1) Hepatic glucose output reduction: Inhibits mitochondrial complex I in hepatocytes, increasing the AMP:ATP ratio, which activates AMPK. AMPK suppresses gluconeogenesis and glycogenolysis, reducing hepatic glucose output by 25-30%. (2) Peripheral insulin sensitization: Enhances insulin receptor signaling and GLUT4 transporter translocation in skeletal muscle, improving glucose uptake by 20-30%. (3) GI glucose absorption: Mildly reduces intestinal glucose absorption and increases intestinal glucose utilization. (4) AMPK-mediated effects: AMPK activation also increases fatty acid oxidation, inhibits lipogenesis, reduces mTOR signaling (relevant for longevity), and improves mitochondrial function. (5) Gut microbiome: Metformin significantly alters gut microbiota composition in ways that improve metabolic health.
Oral bioavailability is 50-60% (not affected by food, but GI tolerability is much better with food). Peak plasma concentration in 2-3 hours (IR) or 4-8 hours (XR). NOT protein-bound — distributes freely in tissues. NOT metabolized — excreted unchanged by the kidneys via tubular secretion. This means no hepatic metabolism or drug-drug interactions via CYP enzymes. Half-life of 4-8.7 hours. Accumulates in intestinal wall at concentrations 30-300x higher than plasma levels. Reaches steady state in 24-48 hours.
Typical Dose
Insulin sensitizing (general health): 500mg 1-2x daily. On-cycle metabolic support: 500-1,000mg daily (start low). GH/insulin protocol management: 500-1,500mg daily. Anti-aging/longevity dosing: 500mg 1-2x daily. Maximum dose: 2,000-2,500mg daily (clinical max; most PED users stay at 1,000-1,500mg).
Frequency
Start at 500mg once daily with dinner for 1-2 weeks, then titrate up as tolerated. Split doses with meals (e.g., 500mg with breakfast, 500mg with dinner). Extended Release can be taken once daily with the largest meal.
Administration
Oral tablet. Immediate Release (IR) or Extended Release (XR/ER). ALWAYS take with food to reduce GI side effects. Extended release formulation is strongly preferred for tolerability.
Half-Life
4-8.7 hours (immediate release); 6-8 hours effective with extended release
Contraindications